Private: Gallery Post #1

11

Oct2016
Effective November 1, 2016, the ministry is introducing the application of generic substitution to the Exceptional Access Program (EAP). Under this new policy, if an EAP drug has an interchangeable generic product designated through the Off-Formulary Interchangeable (OFI) mechanism, the ministry will only approve the funding of the generic product. Where ... Read More

04

Oct2016
The Ontario Public Drug Programs (OPDP) is publishing an addendum (Addendum #1) to the Ontario Guidelines for Drug Submission and Evaluation (Guidelines) to assist the manufacturers in making drug submissions to the OPDP. Addendum #1 contains information about the regulatory amendments that were recently approved by the Ontario government and ... Read More

28

Sep2016
Alberta Health amended their price policy on September 26, 2016 to come into effect on October 1, 2016. The following amendments were made: Amendment to the Maximum Allowable (MAC) Price Policy of the Alberta Price Policy Effective October 1, 2016, the MAC Price Policy, section 2-14, will be amended to include eligible ... Read More

26

Sep2016
Recent amendments have been made to the Ontario Regulation 201/96 under the Ontario Drug Benefit Act (‘ODBA Regulation’) and to Regulation 935 under the Drug Interchangeability and Dispensing Fee Act (‘DIDFA Regulation’). The amendments have been approved by the Ontario Government and come into force on October 1, 2016. A notice ... Read More

20

Sep2016
To help drug manufacturers prepare drug submissions, the Ministry of Health and Long-Term Care has updated its Ontario Guidelines for Drug Submission and Evaluation (Guidelines). The Guidelines take effect on October 6, 2016. All submissions received on or after this date must comply. The updated Guidelines reflect current regulatory and policy requirements ... Read More

13

Sep2016
CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian ... Read More

08

Sep2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2016: 40 negotiations are currently underway with 10 files added since the last update of July 31, 2016: Cotellic (cobimetinib): used to treat metastatic melanoma Fabrazyme (agalsidase beta): used to treat ... Read More

26

Aug2016
The Canadian Association for Healthcare Reimbursement (CAHR) is hosting Market Access 201-Fundamentals of Reimbursement in Canada. This one-day training course is a continuation of Market Access 101 and offers a deeper dive into Market Access strategies. The program will be emceed by Dr. Jeffery Hoch from the Department of ... Read More

26

Aug2016
Information Session on the PMPRB Guidelines Modernization Discussion Paper On August 23rd, 2016, PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, held a free “Information Session on the PMPRB Guidelines Modernization Discussion Paper”. This came shortly after the PMPRB recently releasing its long awaited consultation paper “PMPRB ... Read More

19

Aug2016
2015 Annual Report Released  Earlier today, the Patented Medicine Prices Review Board (PMPRB), in accordance with sections 89 and 100 of the Patent Act, released its Annual Report for the year ended December 31, 2015. The Annual Report is an extensive document that reviews all of the PMPRB’s major activities, analyses of ... Read More